心通口服液联合氨氯地平治疗冠心病心绞痛临床研究

Clinical study on Xintong Oral Liquid combined with amlodipine in treatment of angina pectoris of coronary heart disease

目的探讨心通口服液联合氨氯地平治疗冠心病心绞痛的临床疗效。方法选取2018年10月—2019年12月在天津市第一中心医院就诊的冠心病心绞痛患者226例,随机分为对照组和治疗组,每组各113例。对照组口服苯磺酸左氨氯地平片,5 mg/次,1次/d。治疗组在对照组的基础上口服心通口服液,10~20 mL/次,3次/d。两组患者治疗2个月。观察两组患者临床疗效,同时比较治疗前后两组患者西雅图调查量表(SAQ)评分、血管内皮生长因子水平、心功能、心绞痛发作频率和持续时间。结果治疗后,对照组临床有效率为80.53%,显著低于治疗组的95.58%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者SAQ评分显著高于治疗前(P<0.05),且治疗组患者SAQ评分明显高于对照组(P<0.05)。治疗后,两组患者血管内皮生长因子水平、左室射血分数(LVEF)和心输出量(CO)显著高于治疗前(P<0.05),体血管阻力(SVR)和胸腔液体含量(TFC)显著低于治疗前(P<0.05),且治疗后治疗组患者这些指标水平明显好于对照组(P<0.05)。治疗后,两组心绞痛发作频率和心绞痛持续时间明显下降(P<0.05),且治疗组的心绞痛发作频率和心绞痛持续时间显著低于对照组(P<0.05)。结论心通口服液联合氨氯地平治疗冠心病心绞痛可改善患者心功能和血管内皮生长因子水平,临床疗效显著,具有一定的临床推广应用价值。

Objective To explore the clinical effect of Xintong Oral Liquid combined with amlodipine in treatment of angina pectoris of coronary heart disease.Methods Patients(226 cases)with angina pectoris of coronary heart disease in Tianjin First Central Hospital from October 2018 to December 2019 were randomly divided into control and treatment groups,and each group had 113 cases.Patients in the control group were po administered with Levamlodipine Besylate Tablets,5 mg/time,once daily.Patients in the treatment group were po administered with Xintong Oral Liquid on the basis of the control group,10—20 mL/time,three times daily.Patients in two groups were treated for 2 months.After treatment,the clinical efficacy was evaluated,and the SAQ scores,the VEGF level,cardiac function,the frequency and duration of angina pectoris in two groups before and after treatment were compared.Results After treatment,the clinical efficacy in the control group was 80.53%,which was significantly lower than 95.58%in the treatment group,and there were differences between two groups(P<0.05).After treatment,the SAQ scores in two groups were significantly increased(P<0.05),and which in the treatment group were significantly higher than that in the control group(P<0.05).After treatment,the VEGF level,LVEF and CO in two groups were significantly increased(P<0.05),but the SVR and TFC were significantly decreased(P<0.05),and these indexes in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the frequency and duration of angina pectoris in two groups were significantly decreased(P<0.05),and which in the treatment group were significantly lower than those in the control group(P<0.05).Conclusion Xintong Oral Liquid combined with amlodipine can improve the cardiac function and VEGF level,has a significant clinical effect and a certain clinical application value.